IceCure Medical Ltd (ICCM), Monday announced that the company's next-generation single cryoprobe cryoablation system, the XSense System and CryoProbes, has received regulatory approval from the Medical Device Division of Israel's Ministry of Health.
XSense is now approved in Israel for all indications for which ProSense has already received approval in Israel, including general surgery, dermatology, neurology, including cryoanalgesia, thoracic surgery, ENT, gynecology, oncology, proctology and urology, the company added.
The approval reaffirms IceCure's leadership position in liquid-nitrogen based cryoablation, the company's CEO Eyal Shamir noted.
Currently, ICCM is moving up 8.73 percent, to $1.07 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.